Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — Q2 2022 Earnings Presentation
17 slides from Abcellera Biologics's earnings presentation, Aug 9, 2022
Slide 1: Q2 2022 Business Update
Exhibit 99.2 AbCellera Q2 2022 BUSINESS UPDATE AUGUST 9, 2022 COPYRIGHT ABCELLERA
Slide 2: Disclaimer
DISCLAIMER Q2 2022 BUSINESS UPDATE This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on
Slide 3: Q2 2022 Business Update Summary
Q2 2022. BUSINESS UPDATE SUMMARY. MAINTAINING A STRONG CASH POSITION & EXPANDING COMPETITIVE ADVANTAGE Current environment presents challenges for would-be competitors, extending our competitive advantage significantly. Our business model provides value to companies prioritizing innovation, efficien
Slide 4: Technology as a lever: target to IND is complex and technology-intensive
COPYRIGHT © ABCELLERA Q2 2022. BUSINESS UPDATE TECHNOLOGY AS A LEVER TARGET TO IND IS ONE OF THE MOST COMPLEX & TECHNOLOGY – INTENSIVE PATHS IN ANY SECTOR Target Identification IDEATION Drug Discovery regulations, technology, science, manufacturing, lab space, talent 1000+ steps PRODUCT CREATION 3 t
Slide 5: Significant opportunities to unlock value
VALUE CREATION SIGNIFICANT OPPORTUNITIES TO UNLOCK VALUE We aim to deliver value in three ways: by making drug development faster by doing things that haven't been done before by leveling the playing field for partners, to empower a broad ecosystem of innovators Q2 2022 BUSINESS UPDATE $200M+ NPV by
Slide 6: Partnering with premier venture capital firms to unlock early-stage innovators
Partnership PARTNERING WITH PREMIER VENTURE CAPITAL FIRMS TO UNLOCK EARLY-STAGE INNOVATORS 6 PORTFOLIO COMPANY OF NEW PROGRAMS UNDER CONTRACT ATLAS VENTURE 8 POTENTIAL PROGRAMS undisclosed PORTFOLIO COMPANIES OF VERSANT ventures Q2 2022 BUSINESS UPDATE 3 targets multi-year targets multi-year multipl
Slide 7: T-Cell Engager Platform
TECHNOLOGY DEVELOPMENT T-CELL ENGAGER PLATFORM Q2 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 7 ADVANCING NEW T-CELL ENGAGER CANCER THERAPIES Our data indicate that our CD3 panel of 200+ unique antibodies bind to a wide variety sites on the CD3 complex and is capable of constructing bispecifics antib
Slide 8: Pre-partnered programs: tech development may generate assets for partnering
TECHNOLOGY DEVELOPMENT PRE-PARTNERED PROGRAMS TECH DEVELOPMENT MAY GENERATE ASSETS FOR PARTNERING Pandemic Response Platform 02 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 8 PANDEMIC Response Platform Technology-intensive challenge requiring complex Integration to deliver antibody therapies quickly a
Slide 9: Value of pre-partnered programs
TECHNOLOGY DEVELOPMENT, VALUE OF PRE-PATNERED PROGRAMS Q2 2022 BUSINESS UPDATE 2 YEARS OF TECH DEVELOPMENT 2 COVID ANTIBODY TREATMENTS 2.5M + PATIENTS TREATED We had Spent 2 years developing our technology specially for pandemic response prior to the emergence of COVID-19 and initiated our work befo
Slide 10: Q2 2022 Financials Update
Q2 2022 FINANCIALS UPDATE COPYRIGHT © ABCELLERA 10
Slide 11: Strong portfolio growth
Strong portfolio growth cumulative # of program starts cumulative # of molecules in the clinic total # of programs under contracts 164 total # of discovery partners 38 q2 2022 business update financials (bar graph) -without downstream participation + with downstream participation (bar graph) note: s
Slide 12: Molecules in the clinic
Q2 2022 business update financials 6 molecules in the clinic molecules bamlanivimab (ly-cov555) bebtelovimab (ly-cov1404) nbl-012 nbl-015 undisclosed IVX-01 stage marketed, emergency use authorization (EUA) phase 1 completed IND/CTA authorized IND/CTA authorized IND/CTA authorized clinical field stu
Slide 13: $45.9M total revenue, driven by royalties for bebtelovimab
$45.9M Total revenue, driven by royalties for bebtelovimab. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $27.6M $21.2M $0.3M $1.0M $5.2M Q2 2021 $45.9M $33.2M $12.5M $0.1M Q2 2022 COPYRIGHT © ABCELLERA Q2 2022 BUSINESS UPDATE FINANCIALS 13
Slide 14: Operating expenses reflect strengthening of the platform
Operating expenses reflect strengthening of the platform. Operating Expenses USD RESEARCH & DEVELOPMENT +$11.6M $15.0M $26.7M Q2 2021 Q2 2022 SALES & MARKETING +$1.8M $1.3M Q2 2021 $3.1M Q2 2022 GENERAL & ADMIN +$3.2M $11.2M Q2 2021 $14.4M Q2 2022 COPYRIGHT © ABCELLERA Q2 2022 BUSINESS UPDATE FINANC
Slide 15: Net loss of $6.8M
Net loss of $6.8M: equivalent to $0.02 (basic and diluted) Per share. Earning USD NET EARNINGS -$2.3M Q2 2021 -$6.8M Q2 2022 EARNINGS PER SHARE: BASIC AND DILUTED -$0.01 Q2 2021 -$0.02 Q2 2022 COPYRIGHT © ABCELLERA Q2 2022 BUSINESS UPDATE FINANCIALS 15
Slide 16: Over $1 billion in total cash, equivalents, and marketable securities
Over $1 billion in total cash, equivalents, and marketable securities. Cash Flows USD $748M $247M $476M $25M 31-Dec-21 $373M OPERATING ($54M) INVESTING ($2M) FINANCING ($1M) FX $1,049M $232M Marketable Securities $792M Cash & Equivalents $25M Restricted Cash 30-June-22 COPYRIGHT © ABCELLERA Q2 2022
Slide 17: Thank You
THANK YOU COPYRIGHT © ABCELLERA Q2 2022 BUSINESS UPDATE 17